Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 22 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 09 May 2016 Status changed from recruiting to active, no longer recruiting.